Context
Founded in 2011, Blueberry Therapeutics is a drug discovery and development company focused on creating innovative “nanomedicines” which enhance the delivery of drugs into cells and tissues.
The team focuses on nanomedicines specifically adapted for difficult to treat skin and nail conditions such as; fungal nail infections, athlete’s foot, acne and eczema.
In order to capitalize on growing market demand, management of Blueberry Therapeutics recognized the need to seek external financing in order to fund its development programme for the treatment of these skin problems.
About Blueberry Therapeutics
Blueberry Therapeutics Ltd, founded in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail conditions. The company is using its state of the art nano-formulation technology to develop high-value medicines where a reduced dose and improved drug delivery is needed, to overcome existing tolerability and safety profile concerns. Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects from preclinical research into de-risked human clinical proof of concept and then on to the market.
Bryan, Garnier & Co acts as Financial Advisor to Blueberry Therapeutics on its £10 million Series B Fundraising
Bryan, Garnier & Co acted as the Sole Financial Advisor to Blueberry Therapeutics.
Blueberry Therapeutics was introduced to China Medical Systems by Bryan, Garnier & Co. Over a period of several months both companies established an excellent understanding of their complementary strengths and how to build upon a deal together.
The deal involved an equity investment in Blueberry as well as an agreement for product rights to the wider Chinese market.
The advisory team at Bryan, Garnier & Co has been working with Blueberry Therapeutics since the beginning of 2018 on its funding options.
This transaction marks the 15th healthcare transaction for the practice since the beginning of the year. Other recent landmark transactions have included: Medartis IPO on the SIX Swiss Stock Exchange, Symetis Euronext IPO and subsequent sale to Boston Scientific and the sale of TxCell to Sangamo Therapeutics.
Share